{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Neuronetics, Inc.
Neuronetics, Inc. Hits New 52-Week Low at $1.19 Amid Declining Stock Performance
Neuronetics, Inc. has reached a new 52-week low, reflecting a significant decline in its stock value over the past year, contrasting with broader market gains. Despite a substantial increase in net sales, the company faces challenges, including a notable net loss and concerning financial metrics, indicating limited long-term growth prospects.
Is Neuronetics, Inc. technically bullish or bearish?
As of August 11, 2025, Neuronetics, Inc. shows a mildly bullish trend overall, but mixed signals from various indicators suggest caution due to bearish pressures on the weekly metrics.
Is Neuronetics, Inc. overvalued or undervalued?
As of November 6, 2018, Neuronetics, Inc. is considered risky and overvalued due to high Price to Book and EV to Sales ratios, negative returns on equity and capital employed, and a significantly lower P/E ratio compared to peers, indicating struggles in generating shareholder returns.
Is Neuronetics, Inc. overvalued or undervalued?
As of November 6, 2018, Neuronetics, Inc. is considered overvalued and categorized as risky due to significant negative financial metrics, including a Price to Book Value of 6.91 and a P/E ratio of -5.27, especially when compared to its peers.
Is Neuronetics, Inc. technically bullish or bearish?
As of May 1, 2025, the trend is mildly bullish due to daily moving averages and monthly KST, but caution is advised due to mixed signals from the weekly MACD and Bollinger Bands.
Who are in the management team of Neuronetics, Inc.?
As of March 2022, the management team of Neuronetics, Inc. includes Mr. Brian Farley (Independent Non-Executive Chairman), Mr. Keith Sullivan (President and CEO), and Directors Mr. John Bakewell, Ms. Sheryl Conley, Dr. Wilfred Jaeger, and Mr. Glenn Muir. They are responsible for the company's strategic direction and operations.
What does Neuronetics, Inc. do?
Neuronetics, Inc. is a medical technology company that develops devices for treating psychiatric disorders, with a market cap of approximately $229.71 million. As of March 2025, it reported net sales of $32 million and a net loss of $13 million.
How big is Neuronetics, Inc.?
As of Jun 18, Neuronetics, Inc. has a market capitalization of 229.71 million and reported net sales of 89.45 million with a net profit of -48.02 million over the latest four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
